Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- 'Super drug' for pediatric blood cancer may soon be reality on December 24, 2018 at 8:00 pm
New York, Dec 24 : A "super drug" that helps slow down the progression of blood cancer in children could soon become a reality, say researchers. Patients with leukemia have a very low percentage of re... […]
- Childhood Cancer Survivors Reunite, Marry At Hospital That Saved Their Lives on December 24, 2018 at 9:32 am
Their diagnoses were devastating: Joel had osteosarcoma, a form of bone cancer, and Lindsey had acute lymphoblastic leukemia. Doctors recommended they both seek treatment at St. Jude Children’s ... […]
- “Super Drug” for Pediatric Leukemia Could Become Reality on December 24, 2018 at 6:14 am
Investigators at the Northwestern University Feinberg School of Medicine have just presented new data that shows when a key protein responsible for leukemia—dubbed mixed-lineage leukemia 1 (MLL1)—is s... […]
- New 'Super Drug' In Development Could Become A Powerful Tool Against Pediatric Leukemia on December 24, 2018 at 3:52 am
Currently, leukemia is the world’s most common form of cancer in children and teens affecting thousands across the globe. A devastating malignant, and progressive disease, leukemia is when bone ... […]
- Prospect Park kindergarten student battling leukemia makes gift bags for sick kids on December 24, 2018 at 2:21 am
She also hopes the page will create awareness for childhood cancer, an affliction which people rarely want to talk about or discuss openly. “Honestly, even I couldn’t say the word ‘Leukemia’ for a rea... […]
- Pediatric leukemia ‘super drug’ could be less than a decade away on December 23, 2018 at 4:27 pm
Two new experimental pediatric leukemia treatments are to be turned into one single drug, with human trials beginning over the next few years(Credit: vitanovski/Depositphotos) Building on ... […]
- Savannah community support helps family through child's leukemia treatment, birth of new baby on December 22, 2018 at 6:00 pm
Initial tests and symptoms indicated the startling possibility of leukemia. The next few days were like a blur for the family. Lily was moved to the pediatric intensive care unit at Memorial Health an... […]
- Pediatric leukemia ‘super drug’ could be developed in the coming years on December 22, 2018 at 9:26 am
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the ... […]
- Children’s Hospital Los Angeles Receives $1.2 Million to Study Drug Resistance in Leukemia on December 21, 2018 at 3:41 pm
Children’s Hospital Los Angeles was awarded a $1.2 million federal grant to study drug resistance in leukemia. The East Hollywood hospital announced Dec. 20 that the National Institute of Health ... […]
via Bing News